ArticleeLife2019
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Macrophage-associated kinase signaling in atherosclerosis - a systematic review.Cell communication and signaling : CCS · 2026Pooled it
- Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors.The Journal of clinical investigation · 2026Article
- RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer.Cell reports · 2026Article
- Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- FAK inhibitor suppresses ovarian cancer growth by inhibiting tumor angiogenesis.Cancer cell international · 2026Article
- Disarming cancer resistance: FAK as a therapeutic target.Trends in cancer · 2026Review
- FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages.Cell reports · 2026Article
- Targeting Phosphoinositide 3-Kinase to Reduce the Progression of Ovarian Cancer Cells in a 3D Collagen Model.Biomolecules · 2026Article
- Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition.JCI insight · 2026Article
- Focal Adhesion and Cancer Cell Cycle-Associated Resistance.ACS omega · 2026Review
- Resibufogenin and Oxaliplatin Synergistically Inhibit Diffuse Gastric Cancer by Inactivating the FAK/AKT/GSK3β/β-Catenin Signaling Pathway.Recent patents on anti-cancer drug discovery · 2026Article
- Research progress on the influence of tumor microenvironment on immunotherapy for pancreatic ductal adenocarcinoma.Open medicine (Warsaw, Poland) · 2026Review
- Ovarian Tumor FAK Inhibition Releases Omega-3 Fatty Acids Stimulating GATA6 Peritoneal Macrophage CXCL13 Production Enhancing Immunotherapy.bioRxiv : the preprint server for biology · 2025Article
- Article
- Transforming Cancer Therapy: Unlocking the Potential of Targeting Vascular and Stromal Cells in the Tumor Microenvironment.Cancer research · 2025Review
- Inducible FAK loss but not FAK inhibition in endothelial cells of PYK2-null mice activates p53 tumor suppressor to prevent tumor growth.Molecular biology of the cell · 2025Article
- Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2025Review
- CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Emerging strategies and translational advancements of DDR1 in oncology.Discover oncology · 2025Review
- PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State.Cancer discovery · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 7 institutions in 4 countries.
Carlos J Diaz Osterman *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Duygu Ozmadenci *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Elizabeth G Kleinschmidt *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Kristin N Taylor *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Allison M Barrie *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Shulin Jiang *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Lisa M Bean *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Florian J Sulzmaier *Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Christine JeanDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Isabelle TancioniDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Kristen AndersonDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Sean UryuDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Edward A CordascoDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Jian LiState Key Laboratory of Cellular Stress Biology, Innovation Center for Cellular Signaling Network, School of Life Sciences, Xiamen University, Xiamen, China.
Xiao Lei ChenState Key Laboratory of Cellular Stress Biology, Innovation Center for Cellular Signaling Network, School of Life Sciences, Xiamen University, Xiamen, China.
Guo FuState Key Laboratory of Cellular Stress Biology, Innovation Center for Cellular Signaling Network, School of Life Sciences, Xiamen University, Xiamen, China.
Marjaana OjalillDepartment of Biochemistry, University of Turku, Turku, Finland.
Pekka RappuDepartment of Biochemistry, University of Turku, Turku, Finland.ORCID 0000-0002-5068-2842
Jyrki HeinoDepartment of Biochemistry, University of Turku, Turku, Finland.
Adam M MarkDepartment of Medicine, UCSD Center for Computational Biology & Bioinformatics, La Jolla, United States.
Guorong XuDepartment of Medicine, UCSD Center for Computational Biology & Bioinformatics, La Jolla, United States.
Kathleen M FischDepartment of Medicine, UCSD Center for Computational Biology & Bioinformatics, La Jolla, United States.
Vihren N KolevVerastem Oncology, Needham, United States.
David T WeaverVerastem Oncology, Needham, United States.
Jonathan A PachterVerastem Oncology, Needham, United States.
Balázs GyőrffyInstitute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary.
Michael T McHaleDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.
Denise C ConnollyFox Chase Cancer Center, Philadelphia, United States.
Alfredo MolinoloDepartment of Pathology, Moores UCSD Cancer Center, La Jolla, United States.
Dwayne G StupackDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.ORCID 0000-0003-4396-5745
David D SchlaepferDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United States.ORCID 0000-0003-4814-9210
Moores Cancer CenterUniversity of Turku · FIVerastem (United States) · USXiamen University · CNUniversity of California San Diego · USFox Chase Cancer Center · USSemmelweis University · HU
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8MVIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MUC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3MUCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3MRole of Focal Adhesion Kinase In TumorigenesisR01CA102310 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D · 2003 to 2019
$5.0MIntegrins and Caspase 8 in Tumor ProgressionR01CA107263 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STUPACK, DWAYNE G. · 2005 to 2014
$3.1MDissecting FAK-regulated oncogenic signaling programs in ovarian cancerR01CA247562 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D, STUPACK, DWAYNE G. · 2020 to 2024
$2.3MSignaling Connections Controlling Cell Motility and InvasionR01CA180769 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHLAEPFER, DAVID D · 2013 to 2017
$1.9MValidating a mouse model of ovarian cancer for early detection through imagingR01CA195723 · NCI · UNIVERSITY OF ARIZONA · PI BARTON, JENNIFER KEHLET · 2015 to 2016
$1.1MEndocrine Network for Undergraduate Research and Carrier Development OpportunitieT36GM095349 · NIGMS · ENDOCRINE SOCIETY · PI ANDERSON, STEVEN M, LAAKSO, JOSEPH M · 2011 to 2015
$1.1MOGF & Gemcitabine: A Novel Treatment for Pancreatic Cancer: Phase I StudyR03CA129581 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SMITH, JILL P · 2008 to 2009
$155kNCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA102310NCI NIH HHS R01 CA107263NCI NIH HHS R01 CA180769NCI NIH HHS R01 CA195723NCI NIH HHS R01 CA247562NCI NIH HHS T32 CA121938NIGMS NIH HHS T36 GM095349NIH HHS P30 CA006927NIH HHS P30 CA023100NIH HHS RO1 CA102310NIH HHS RO1 CA107263NIH HHS RO1 CA180769NIH HHS RO1 CA195723NIH HHS T32 CA121938NIH HHS T36 GM095349NIH HHS UL1 TR001442
Abstract
Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence. Stem phenotypes involving Wnt-β-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere formation are here associated with spontaneous gains in
Indexed as
Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsCisplatinDisease Models, AnimalFemaleFocal Adhesion Kinase 1HumansMiceOvarian NeoplasmsPlatinumProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Signal TransductionStem CellsAntineoplastic AgentsCisplatinFocal Adhesion Kinase 1KRAS protein, humanMYC protein, humanPlatinumProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)PTK2 protein, humanbeta-catenincancer biologyfocal adhesion kinase FAKmouseovarian cancerplatinum chemotherapypluripotencytumorspheres
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.